Maxime Fastrez

Dr. Maxime Fastrez


Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
28 January 2023 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
LILudovica Imperiale
Ludovica Imperiale
MNMichelle Nisolle
Michelle Nisolle
JNJean-Christophe Noël
Jean-Christophe Noël
MFMaxime Fastrez
Maxime Fastrez
At present, there is no curative treatment for endometriosis. Medical management and surgical treatment do not provide long-term relief. A detailed understanding of its pathophysiology is mandatory in order to facilitate both the diagnosis and treatment. The delay that typically precedes proper diagnosis (6 to 7 years) is probably one of the most challenging aspects of endometriosis management. In 2012, the total cost per woman due to endometriosis was estimated to be 9579€ per year in a multicenter study across the USA and Europe. According to their physiopathology and their localization, ectopic endometrial lesions, consisting of endometrial glands and stroma, can be divided into three different types: superficial peritoneal endometriosis (SPE), ovarian endometrioma (OMA), and deep infiltrating endometriosis (DIE). The following paper aims to review the available data in the literature on the pathogenesis, diagnosis, and treatment of different types of endometriosis.

12 July 2018 in Surgical Innovation
Verified
Journal Article
Closed access
ANAuriane De Neef
Auriane De Neef
GCGuy-Bernard Cadière
Guy-Bernard Cadière
PBPierre Bourgeois
Pierre Bourgeois
RBRomain Barbieux
Romain Barbieux
GDGiovanni Dapri
Giovanni Dapri
MFMaxime Fastrez
Maxime Fastrez
Background. The standard treatment of rectovaginal deep infiltrating endometriosis nodules (RVDIEN) consists in their surgical removal. RVDIEN are anatomically neovascularized. Indocyanine green (ICG) reveals vascularized structures when becoming fluorescent after exposure to near-infrared (NIR) light. This study aims to evaluate if fluorescence-guided surgery can improve the laparoscopic resection of RVDIEN, thus avoiding a rectal perforation. Materials and Methods. Patients with a symptomatic RVDIEN, scheduled for a laparoscopic rectal shaving, were enrolled in the study. Technically, the RVDIEN was targeted and removed with the help of the NIR imager device Image 1 Spies (Karl Storz GmBH & Co KG, Tuttlingen, Germany) or Visera Elite II (Olympus Europe SE & Co KG, Hamburg, Germany), after an intraoperative, intravenous injection of ICG (0.25 mg/kg). Results. Six patients underwent a fluorescence-guided laparoscopic shaving procedure for the treatment of a nonobstructive RVDIEN. Fluorescence of the RVDIEN was observed in all the patients. In one patient, once the main lesion was removed, the posterior vaginal fornix still appeared fluorescent and was removed. No intraoperative rectal perforation occurred. The postoperative hospital stay was 2 days. No postoperative rectovaginal fistula occurred within a median follow-up of 16 months (range = 2-23 months). Conclusion. In this preliminary study, fluorescence-guided laparoscopy appeared to help in separating the RVDIEN from the healthy rectal tissue, without rectal perforation. Moreover, this technique was helpful in deciding if the resection needed to be enlarged to the posterior vaginal fornix.

16 April 2013 in Acta Obstetricia et Gynecologica Scandinavica
Verified
Journal Article
Closed access
PDF file
MFMaxime Fastrez
Maxime Fastrez
FGFrédéric Goffin
Frédéric Goffin
IVIgnace Vergote
Ignace Vergote
JVJean Vandromme
Jean Vandromme
PPPhilippe Petit
Philippe Petit
MDMichel Degueldre
Michel Degueldre

1 June 2011 in Reproductive Sciences
Verified
Journal Article
Closed access
MFMaxime Fastrez
Maxime Fastrez
CNC. Nogarède
C. Nogarède
MTM. Tondeur
M. Tondeur
NSN. Sirtaine
N. Sirtaine
SRS. Rozenberg
S. Rozenberg

1 December 2009 in European Journal of Obstetrics & Gynecology and Reproductive Biology
Verified
Journal Article
Closed access
MFMaxime Fastrez
Maxime Fastrez
JVJean Vandromme
Jean Vandromme
PGPascale George
Pascale George
SRSerge Rozenberg
Serge Rozenberg
MDMichel Degueldre
Michel Degueldre

29 April 2020 in Cancers
Verified
Journal Article
Open access
PDF file
KNKristyna Nemejcova
Kristyna Nemejcova
RKRoman Kocian
Roman Kocian
Christhardt KohlerChristhardt Kohler
Christhardt Kohler
JJJiri Jarkovsky
Jiri Jarkovsky
JKJaroslav Klát
Jaroslav Klát
DCDavid Cibula
David Cibula
The quality of pathological assessment is crucial for the safety of patients with cervical cancer if pelvic lymph node dissection is to be replaced by sentinel lymph node (SLN) biopsy. Central pathology review of SLN pathological ultrastaging was conducted in the prospective SENTIX/European Network of Gynaecological Oncological Trial (ENGOT)-CX2 study. All specimens from at least two patients per site were submitted for the central review. For cases with major or critical deviations, the sites were requested to submit all samples from all additional patients for second-round assessment. From the group of 300 patients, samples from 83 cases from 37 sites were reviewed in the first round. Minor, major, critical, and no deviations were identified in 28%, 19%, 14%, and 39% of cases, respectively. Samples from 26 patients were submitted for the second-round review, with only two major deviations found. In conclusion, a high rate of major or critical deviations was identified in the first round of the central pathology review (28% of samples). This reflects a substantial heterogeneity in current practice, despite trial protocol requirements. The importance of the central review conducted prospectively at the early phase of the trial is demonstrated by a substantial improvement of SLN ultrastaging quality in the second-round review.